

Ref: Syn/CS/SE/PR/Mar 2018

**Syngene**

**Syngene International Limited**  
Biocon Park SEZ, Bommasandra IV Phase,  
Jigani Link Road, Bangalore 560 099, India.  
T +91 80 2808 2808  
F +91 80 4014 3150 / 2852 3423  
CIN No. L85110KA1993PLC014937

[www.syngeneintl.com](http://www.syngeneintl.com)

March 26, 2018

To, The Manager Listing The BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 <b>Scrip Code: 539268</b>	To, The Manager Listing The National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 <b>Scrip Symbol: SYNGENE</b>
---	---

Dear Sir/Madam,

**Subject: Press Release**

This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **“Syngene International Signs R&D Agreement with GSK”**.

The above mentioned press release will also be available on website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

This is for your information and records.

Thanking You,

Yours faithfully,  
For **SYNGENE INTERNATIONAL LIMITED**

For Mayank Verma  
**Company Secretary**



Anil Kumar Panchariya  
Asst. Company Secretary





## PRESS RELEASE

# Syngene International Signs R&D Agreement with GSK

Syngene scientists to work with GSK to advance drug discovery  
in multiple therapeutic areas

26 March 2018, Bangalore, India

Syngene International, a leading global contract research services company, today announced an R&D agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms.

As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists, will work closely with GSK's global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world's most pressing healthcare needs.

Syngene started offering Discovery services to global R&D focused organizations from 1994 onwards. Over the years, the Company has consolidated its leadership position in offering integrated discovery, development and manufacturing services across small and large molecules within both the pharmaceutical and biotechnology industries.

Commenting on the collaboration, **Jonathan Hunt, Chief Executive Officer, Syngene International**, said,

### About Syngene

Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is India's largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides. It brings together a state-of-the-art infrastructure spread across 1.3 Mn sq. ft and a highly experienced team of over 3100 scientists,

## PRESS RELEASE

to help R&D focused organizations improve their efficiency and reduce product development time. In FY2017, Syngene serviced 293 clients including 8 of the top 10 global pharma companies as well as industry leaders in segments like biotechnology, nutrition, animal health, consumer goods and specialty chemicals. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com).

**For further information, please reach out to:**

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: <a href="mailto:chanderlekha.nayar@syngeneintl.com">chanderlekha.nayar@syngeneintl.com</a>	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: <a href="mailto:sandeep.nair@syngeneintl.com">sandeep.nair@syngeneintl.com</a>